Thread: Ingen Technologies Inc. - IGNT

EVRN
another one to keep an eye on , its running stable on the RSI line @ 44.60 but i really do believe this is another one thats a low risk and is over due to start to make a nice move,they ave a great line of all natural products thats starting to get the puplics attention expect this to get hot put it on your to watch list!!!!!

Ingen Brings Aboard CDM Capital to Assist With SEC Reporting Obligations
CEO Live Radio Interview Discusses Improving Shareholder Value

Press Release
Source: Ingen Technologies, Inc.
On 8:15 am EST, Tuesday November 10, 2009

YUCAIPA, Calif., Nov. 10, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the company has engaged CDM Capital, LLC to assist with the internal financial reporting and controls as they are related to the most current SEC reporting obligations. In addition to this news, CEO Scott Sand will discuss why the company is focused on its investor needs later today, November 10, 2009 at 11:34AM eastern standard time on The Money Channel's American Scene Radio with host Steve Crowley.



The Newport Beach-California based CDM Capital LLC offers a wide range of pre and post public entity support services in areas such as structuring, capitalization, public relations, investor relations, financial reporting, compliance, market support and exit strategies. The firm provides additional services related to increasing the valuation, and access the U.S. capital markets by listing it as an Over-the-Counter (OTC) publicly traded company.



Specifically, the company and CDM Capital have engaged in a two month contract where CDM shall render financial consulting services to Ingen in matters relating to the restatement, as necessary, of Ingen's financials for the year ended May 31, 2007 and May 31, 2008, working with Ingen's accounting department, outside service providers, and its auditor to prepare and submit the delinquent SEC Reports (Form 10-Q for the period ended November 30, 2008, Form 10-Q for the period ended February 28, 2009, Form 10-K for the year ended May 31, 2009, and Form 10-Q for the period ended August 31, 2009) and prepare reports and financial statements for posting on Pink Sheets -- Electronic Quotation and Trading System for OTC Securities.



"The company is focused on finalizing the SEC filings and the reports required with the OTC Pinks. The new auditors and CDM Capital have reviewed the events with our previous auditors and are comfortable with preparing the filings that are required. The company has heavily invested in improving its SEC reporting for its shareholders, investors and future shareholders. We will also consider extending CDM Capital's services to include working with our investment banking group, Pacific Pearl Group, with increasing the company's valuation. Keep in mind that there are several opportunities for an acquisition of Ingen by other candidates currently in discussions with Pacific Pearl Group. Part of increasing shareholder value by improving our financial team of experts and moving to the OTC-Bulletin Board," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.



Services - Microcap Reverse Merger and Financing Advisory



The Money Channel // American Scene Radio // WallStreetCast



Ingen Technologies,Inc. - Home

What's holding this back?

Ingen Will Exhibit the Oxyview Nasal Cannula at AARC
CEO Live Radio Broadcast Talks About the AARC Convention

Press Release
Source: Ingen Technologies, Inc.
On 8:15 am EST, Monday November 16, 2009

YUCAIPA, Calif., Nov. 16, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that the company is an exhibitor at the American Association of Respiratory Care (AARC) 55th international respiratory congress in San Antonio-Texas next month, Further, CEO, Scott Sand, will discuss the AARC exhibition tomorrow November 17, 2009 at 11:34AM eastern standard time on The Money Channel's American Scene Radio with host Steve Crowley.



Since 1947, the American Association for Respiratory Care (AARC) has been committed to enhancing professionalism as a respiratory care practitioner, improving performance on the job, and helping to broaden the scope of knowledge essential to the clinician's success. With more than 47,000 members nationwide, the AARC is the only professional society for respiratory therapists in hospitals and with home care companies, managers of respiratory and cardiopulmonary services, and educators who provide respiratory care training.



The company is an exhibitor at this year's 55th International Congress of the American Association of Respiratory Care held in San Antonio, Texas from December 5th through December 7th, 2009. The company will show-case the new Oxyview Nasal Cannula in a priority corner booth no. 381. "This is a very important exhibit for Ingen to attend to introduce the new Oxyview Nasal Cannula to the respiratory therapists and hospitals worldwide. Our marketing staff attending will give away more than 2000 samples of our products to the other exhibitors and attendees, as well as a newly designed 2 page product brochure, several thousand issues of the new Medco Forum Oxyview publication and the most recently published COPD Digest with the Oxyview Nasal Cannula ad on the back cover," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

Slowly forming a strong base at .0025 .0026 and a higher high yesterday (.003) makes this stock more attractive imo. Still holding and watching here

Ingen Will Exhibit the Oxyview Nasal Cannula at AARC
Nov. 16, 2009 (GlobeNewswire) --
YUCAIPA, Calif., Nov. 16, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that the company is an exhibitor at the American Association of Respiratory Care (AARC) 55th international respiratory congress in San Antonio-Texas next month, Further, CEO, Scott Sand, will discuss the AARC exhibition tomorrow November 17, 2009 at 11:34AM eastern standard time on The Money Channel's American Scene Radio with host Steve Crowley.

Since 1947, the American Association for Respiratory Care (AARC) has been committed to enhancing professionalism as a respiratory care practitioner, improving performance on the job, and helping to broaden the scope of knowledge essential to the clinician's success. With more than 47,000 members nationwide, the AARC is the only professional society for respiratory therapists in hospitals and with home care companies, managers of respiratory and cardiopulmonary services, and educators who provide respiratory care training.

The company is an exhibitor at this year's 55th International Congress of the American Association of Respiratory Care held in San Antonio, Texas from December 5th through December 7th, 2009. The company will show-case the new Oxyview Nasal Cannula in a priority corner booth no. 381. "This is a very important exhibit for Ingen to attend to introduce the new Oxyview Nasal Cannula to the respiratory therapists and hospitals worldwide. Our marketing staff attending will give away more than 2000 samples of our products to the other exhibitors and attendees, as well as a newly designed 2 page product brochure, several thousand issues of the new Medco Forum Oxyview publication and the most recently published COPD Digest with the Oxyview Nasal Cannula ad on the back cover," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

Welcome

American Association for Respiratory Care

MedOx Corporation - Welcome

Ingen Technologies,Inc. - Home

About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

CONTACT: Ingen Technologies, Inc.
Jeff Morgan
909-790-7180
Ingen Technologies,Inc. - Home

Looking for a few more .0027s here today. Just like that we didnt really touch .0026 this week.

Possible news THE CLOSE WATCH FOR IT!

YUCAIPA, Calif., Nov. 20, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the company is now marketing direct to the hospital and therapy respiratory markets. Ingen's CEO, Scott Sand, will discuss these new markets this coming Tuesday, November 24, 2009 at 11:34AM eastern standard time on The Money Channel's American Scene Radio with host Steve Crowley.


According to the most recent report published in June 2009 and made available on the Global Market Research Information Network, respiratory market revenues are high currently, with good potential for sales increases. As the patient population grows and respiratory diseases become more prevalent, the market has the potential for continued growth in many countries and therapeutic areas. There is a great demand for products that provide therapeutic and commercial benefits in this demanding and competitive market. The developing markets of Asia, Latin America and Europe will drive sales increases in particular.



The company is introducing its new Oxyview Nasal Cannula at the America Association of Respiratory Care (AARC) on December 5 - 7, 2009 as an exhibitor. There are 47,000 members of AARC who are hospital based clinicians, therapists and managers, and a large majority will be attending this annual meeting in San Antonio, Texas.



"Our focus has been home health care markets and this is going very smoothly with an increase in sales from home oxygen patients and oxygen providers. Our GSA application is expected to be approved in the near future, and with the growing hospital markets in respiratory care, the Oxyview Nasal Cannula will be an attractive device for hospital nursing as it has shown to save time and provide additional assurance of oxygen flow. Our near final ISO Certification expected in late December 2009 and our recent issue/publication of our patent in the People's Republic of China is in alignment with the future demand for our Oxyview Nasal Cannula in various export countries according to the most recent studies," stated Scott Sand, Chief Executive Officer and Chairman of the Board.



World Respiratory Disorders Market 2009-2024



Welcome



American Association for Respiratory Care



MedOx Corporation - Welcome



Ingen Technologies,Inc. - Home



About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants, with issued patents in China and the USA, and pending patents in Japan, Canada and European Communities expected to be issued in 2010. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.



The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.



Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.






Contact:
Ingen Technologies, Inc.Jeff Morgan909-790-7180www.info@ingen-tech.com

IGNT Video chart 11 20 09